With $2M in hand, neonatal startup Tellus Therapeutics plans future raise wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.
by Chantal Allam, NCBiotech writer May 13, 2021 .
RESEARCH TRIANGLE PARK – Tellus Therapeutics is pushing ahead with developing its neonatal brain injury treatment after landing crucial seed funding this week.
The Durham-based biotech company focused on neonatal health announced that it had secured an undisclosed sum from Boston-based Xontogeny to advance its lead TT-20 program.
The program targets diffuse white matter injury (DWMI) in preterm infants less than 32 weeks gestational age.
Tellus
“We are excited to team up with Tellus to support them in pursuing their mission to provide a treatment for every baby born at risk for brain injury and improve neurodevelopmental outcomes for affected children,” said Xontogeny’s founder and CEO Chris Garabedian.